Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Abbott Laboratories (ABT) A Good Stock To Buy?

Page 1 of 2

Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Micron and Anadarko Petroleum, have not done well during the last 12 months ending in October due to various reasons. Nevertheless, the data show elite investors’ consensus picks have done well on average. The top 30 S&P 500 stocks among hedge funds at the end of September 2014 yielded an average return of 9.5% during the last four quarters ending in October and sixty three percent of these 30 stocks outperformed the market. S&P 500 Index returned only 5.2% during the same period and less than 49% of its constituents managed to beat this return. Because their consensus picks have done well, we pay attention to what elite funds think before doing extensive research on a stock. In this article, we take a closer look at Abbott Laboratories (NYSE:ABT) from the perspective of those elite funds.

Is Abbott Laboratories (NYSE:ABT) a sound investment today? The best stock pickers are becoming more confident. The number of bullish hedge fund bets went up by 6 recently. ABT was in 55 hedge funds’ portfolios at the end of the third quarter of 2015. There were 49 hedge funds in our database with ABT positions at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as ConocoPhillips (NYSE:COP), Danaher Corporation (NYSE:DHR), and Colgate-Palmolive Company (NYSE:CL) to gather more data points.

Follow Abbott Laboratories (NYSE:ABT)
Trade (NYSE:ABT) Now!

Today there are several tools that stock market investors have at their disposal to analyze publicly traded companies. A duo of the less utilized tools are hedge fund and insider trading signals. Our researchers have shown that, historically, those who follow the best picks of the top hedge fund managers can outpace the broader indices by a superb margin (see the details here).

With all of this in mind, we’re going to check out the recent action surrounding Abbott Laboratories (NYSE:ABT).

How have hedgies been trading Abbott Laboratories (NYSE:ABT)?

At Q3’s end, a total of 55 of the hedge funds tracked by Insider Monkey were long this stock, a change of 12% from one quarter earlier. With the smart money’s capital changing hands, there exists a select group of key hedge fund managers who were upping their stakes meaningfully (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Pzena Investment Management, managed by Richard S. Pzena, holds the most valuable position in Abbott Laboratories (NYSE:ABT). Pzena Investment Management has an $208.7 million position in the stock, comprising 1.3% of its 13F portfolio. On Pzena Investment Management’s heels is Cliff Asness of AQR Capital Management, with an $152.8 million position; the fund has 0.3% of its 13F portfolio invested in the stock. Other hedge funds and institutional investors with similar optimism consist of Dmitry Balyasny’s Balyasny Asset Management, Arthur B Cohen and Joseph Healey’s Healthcor Management LP and Phill Gross and Robert Atchinson’s Adage Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!